With Debt-Fueled Megafund, MIT Economists Float Idea For Biopharma Woes
This article was originally published in Start Up
A trio of MIT economists propose a multibillion-dollar biotech fund that deploys asset financing, a lot of leverage, and other financial tricks. It’s a provocative idea, but current biotech investors have their doubts.
You may also be interested in...
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.